Study of Nalbuphine ER in Participants With Hepatic Impairment

NCT04020016 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Nalbuphine ER

Sponsor

Trevi Therapeutics

Collaborators

[object Object]